tetano
Editor, Senior Moderator
Inflammopharmacology
. 2023 Aug 21.
doi: 10.1007/s10787-023-01309-7. Online ahead of print. Ibuprofen, other NSAIDs and COVID-19: a narrative review
William Laughey[SUP] 1 2 [/SUP], Imran Lodhi[SUP] 3 [/SUP], Graham Pennick[SUP] 3 [/SUP], Lucinda Smart[SUP] 3 [/SUP], Olutoba Sanni[SUP] 3 [/SUP], Suneet Sandhu[SUP] 3 [/SUP], Bruce Charlesworth[SUP] 3 [/SUP]
Affiliations
At the start of the coronavirus disease 2019 (COVID-19) pandemic (March 2020), there was speculation that non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen, used to manage some of the symptoms of COVID-19, could increase the susceptibility to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and negatively impact clinical outcomes. In the absence of any robust mechanistic and clinical evidence, this speculation led to confusion about the safety of ibuprofen, contributing to the so-called 'infodemic' surrounding COVID-19. A wealth of evidence has been generated in subsequent years, and this narrative review aims to consider the body of in vitro and in vivo research, observational studies, systematic reviews and meta-analyses on the use of NSAIDs, including ibuprofen, in COVID-19. Overall, the direction of evidence supports that NSAIDs do not increase susceptibility to infection, nor worsen disease outcomes in patients with COVID-19. Neither do they impact the immune response to COVID-19 vaccines. There is no basis to limit the use of NSAIDs, and doing so may deprive patients of effective self-care measures to control symptoms.
Keywords: COVID-19; Ibuprofen; NSAIDs.
. 2023 Aug 21.
doi: 10.1007/s10787-023-01309-7. Online ahead of print. Ibuprofen, other NSAIDs and COVID-19: a narrative review
William Laughey[SUP] 1 2 [/SUP], Imran Lodhi[SUP] 3 [/SUP], Graham Pennick[SUP] 3 [/SUP], Lucinda Smart[SUP] 3 [/SUP], Olutoba Sanni[SUP] 3 [/SUP], Suneet Sandhu[SUP] 3 [/SUP], Bruce Charlesworth[SUP] 3 [/SUP]
Affiliations
- PMID: 37603158
- DOI: 10.1007/s10787-023-01309-7
At the start of the coronavirus disease 2019 (COVID-19) pandemic (March 2020), there was speculation that non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen, used to manage some of the symptoms of COVID-19, could increase the susceptibility to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and negatively impact clinical outcomes. In the absence of any robust mechanistic and clinical evidence, this speculation led to confusion about the safety of ibuprofen, contributing to the so-called 'infodemic' surrounding COVID-19. A wealth of evidence has been generated in subsequent years, and this narrative review aims to consider the body of in vitro and in vivo research, observational studies, systematic reviews and meta-analyses on the use of NSAIDs, including ibuprofen, in COVID-19. Overall, the direction of evidence supports that NSAIDs do not increase susceptibility to infection, nor worsen disease outcomes in patients with COVID-19. Neither do they impact the immune response to COVID-19 vaccines. There is no basis to limit the use of NSAIDs, and doing so may deprive patients of effective self-care measures to control symptoms.
Keywords: COVID-19; Ibuprofen; NSAIDs.